Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

First-in-Class Vepdegestrant Approved in Advanced Breast Cancer

1 articles · 1 outlets · spread 0.00

First-in-Class Vepdegestrant Approved in Advanced Breast Cancer
FDA approval2 d ago

First-in-Class Vepdegestrant Approved in Advanced Breast Cancer

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0010 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • MedPage Today·May 1

    First-in-Class Vepdegestrant Approved in Advanced Breast Cancer

    — Oral agent in second-line more than doubled median PFS in patients with ESR1 mutations May 1, 2026 • 2 min read The FDA approved oral vepdegestrant (Veppanu) for adults with advanced or metastatic estrogen receptor (ER)-positive/HER2-negative breast cancer, the agency announced on Friday. Approval of the first-in-class proteolysis targeting chimera (PROTAC) -- a type of heterobifunctional protein degrader therapy -- stipulates use in patients with ESR1-mutated disease that has progressed following at least one line of endocrine therapy. Findings of the global phase III VERITAC-2 trial showed that among patients with ESR1-mutated disease, vepdegestrant reduced the risk of disease progression or death by 43% compared with fulvestrant (Faslodex), with a median progression-free survival (PFS) of 5 months versus 2.1 months, respectively (HR 0.57, 95% CI 0.42-0.77, P=0.0001). "For patients living with ESR1 mutant, [ER-positive/HER2-negative] advanced breast cancer, there have been minimal second-line treatment options once standard therapies are no longer effective," investigator Erika Hamilton, MD, of the Sarah Cannon Research Institute in Nashville, Tennessee, said in a press release from drugmaker Arvinas. "The introduction of a new, targeted treatment is an encouraging development for this community and highlights meaningful innovation in the way this disease is treated," Hamilton added.

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

MedPage Today

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.